For personal use only

ASX ANNOUNCEMENT

19 June 2026 **ASX ANNOUNCEMENT**

CONNEQT Successfully Raises A$5.5 Million via a Two Tranche Placement to Support Continued Commercial Growth

Highlights:

- Firm commitments received to raise A$5.5 million strongly supported by existing and new shareholders.
- Funds to support continued commercial growth of CONNEQT Pulse, clinical & enterprise expansion initiatives, new product development, and working capital.
- Placement priced at A$0.022 per share, representing a 15.4% discount to the last closing price of A$0.026.
- C2 Ventures associated with Niall Cairns (Chairman) and Craig Cooper (CEO/Managing Director) have committed to take up $1.5m subject to shareholder approval at an Extraordinary General Meeting.
- Existing eligible shareholders are to be offered the opportunity to participate through a Non-underwritten Share Purchase Plan on the same terms as the Placement.

Placement

The Company has received firm commitments to raise approximately A$5.5 million through the issue of approximately 250 million new fully paid ordinary shares at an issue price of A$0.022 per share ("Placement").

The Placement was strongly supported by existing shareholders and new sophisticated and professional investors. The Placement price of A$0.022 per share represents a 15.4% discount to the last closing price of A$0.026 on 16 June 2026.

The Placement shares will be issued in two tranches. The First Tranche Placement shares comprise 160,883,474 shares (96,530,085 shares under ASX Listing Rule 7.1 placement capacity, and 64,353,289 shares under the Company's ASX Listing Rule 7.1A placement capacity), the shares are expected to be issued on Thursday, 25 June 2026.

The Second Tranche of the Placement comprising 89,116,525 shares is expected to be issued following receipt of shareholder approval at an Extraordinary General Meeting of the Company, the details of which will be advised in due course.

For personal use only

Proposed Share Purchase Plan

CONNEQT intends to offer eligible shareholders the opportunity to participate in a Share Purchase Plan at the same issue price as the Placement.

The SPP is expected to raise up to approximately A$0.5 million. The Company reserves the right to accept oversubscriptions or scale back applications at its discretion.

Further details for the SPP, including eligibility criteria and timetable, will be announced separately.

Use of Funds

Funds raised from the Placement will be used for:

- Product inventory to support sales growth;
- IP and new product development;
- Marketing, sales, and enterprise growth initiatives; and
- Working capital and costs of the Placement.

Continued Commercial Momentum

The capital raising follows a period of strong commercial progress across the Company's consumer and enterprise channels.

As disclosed in the March 2026 Quarterly Activities Report, CONNEQT achieved quarterly revenue of A$2.04 million and exited the quarter at an annualised group revenue run-rate of approximately A$10 million. The Pulse arterial health monitor remains the Company's primary growth driver, contributing approximately A$7 million of annualised revenue run-rate at the end of the quarter, and averaging over 50% quarter on quarter growth since launch.

During the March quarter, CONNEQT Pulse was recognised by the American Association of Retired Persons as one of the "Best Blood Pressure Monitors of 2026" and received the highest rating for "Most Comprehensive Data", providing further independent validation of the product's market positioning and clinical capabilities.

The Company's enterprise channel also continues to gain traction, with the initial pilot programmes achieving a 100% conversion rate to commercial contracts, and active clinical subscription sites continuing to increase as at the end of the March quarter. Management continues to see strong opportunities to expand this higher-margin recurring revenue segment.

For personal use only

CONNEQT has also continued to streamline its operating model, reducing monthly operating expenses (excluding non-cash items, cost of goods sold and customer acquisition costs) by approximately 30% since Q3 FY25, improving scalability and supporting the Company's path toward profitability.

Craig Cooper, CEO, CONNEQT Health commented:

"This capital raising positions CONNEQT to accelerate the strong commercial momentum we have established since launching the CONNEQT Pulse just 17 months ago.

In that relatively short period, we have transformed the business from a traditional medical device company into a scalable connected health platform. Since launch, Pulse revenues have grown at an average rate of more than 50% quarter-on-quarter, helping drive the Company to an annualised revenue run-rate of approximately A$10 million. At the same time, we have expanded our enterprise channel, grown our recurring revenue opportunities, secured important commercial partnerships and reduced our operating cost base by approximately 30%.

Importantly, we believe we are still in the early stages of a significant growth opportunity. Demand for the Pulse continues to increase, our enterprise channel is gaining traction, and we are continuing to expand our ecosystem of software, subscription, clinical and data-driven revenue opportunities. The additional capital will allow us to support growing inventory requirements, accelerate product and software development, expand marketing and distribution initiatives, and continue investing in the high-margin recurring revenue streams that underpin long-term value creation.

We are grateful for the strong support received from both existing and new investors in the Placement. We are also pleased to provide existing shareholders with the opportunity to participate in the Share Purchase Plan on the same terms as the Placement.

The progress we have delivered over the past 17 months demonstrates our ability to execute and scale, and both the Board and management team remain highly confident in the opportunities ahead.

I believe the SPP provides eligible shareholders with a compelling opportunity to participate alongside existing and new investors at the same issue price as the Placement in order to position themselves for the next phase of the Company's growth.

That confidence is reflected in the ongoing support of the Company's largest shareholders, including Chairman Niall Cairns and myself through C2 Ventures, which has committed A$1.5 million to the Placement, subject to shareholder approval.

We remain focused on building a category-leading cardiovascular health platform and creating long-term shareholder value."

For personal use only

Indicative Timetable

Event	**Date**
Trading Halt and Placement Opens	17 June 2026
Placement Announcement and Trading Halt Lifted	19 June 2026
Settlement of Placement Shares	24 June 2026
Allotment of Placement Shares	25 June 2026

The above timetable is indicative only and subject to change.

Stralis Capital Partners acted as Sole Lead Manager to the Placement and will receive fees comprising:

(a) 3% of the Gross Proceeds under the Placement as management fee;
(b) 3% of the Net Proceeds under the Placement as selling fee; and
(c) 1% of the Gross Proceeds under the Share Purchase Plan (SPP) as the SPP Advisory Fee.

"Gross Proceeds" refers to the total amount raised under either the Placement or SPP.

"Net Proceeds" refers to the amount raised which excludes the participation of C2V, directors of the Company, and any others as agreed to be excluded by the parties (if applicable).

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations
Rod Hinchcliffe
rod.hinchcliffe@mcpartners.com.au

Media Relations
Melissa Hamilton
melissa.hamilton@mcpartners.com.au

For personal use only

About CONNEQT HEALTH

CONNEQT Health's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market-leading SphygmoCor® vascular biomarker technology. CONNEQT Health is listed on the Australian Stock Exchange ("ASX: CQT").